Day to day, progress just inches along on a construction project, but a time-lapse video can zip through two years in about two minutes. The video above puts CSL’s new headquarters building on fast forward as it comes together in Melbourne, Australia.
CSL – a global biotech that makes medicines for people with rare and serious diseases, as well as vaccines – expects to take possession of its new headquarters in December or January and move staff in by April 2023. The facility includes world-class labs, collaborative office spaces and a Biotech Incubator Laboratory in partnership with the University of Melbourne and the Walter and Eliza Hall Institute (WEHI).
Following a recent acquisition, CSL’s businesses now include CSL Vifor*, a leader in nephrology and iron deficiency; CSL Behring, which develops and delivers medicines for patients who have primary immunodeficiency, hemophilia and other diseases; CSL Plasma, one of the world’s largest collectors of plasma used solely for the production of life-saving medicines; and CSL’s vaccine business, CSL Seqirus*.
* CSL will follow the required legal processes of formally changing the names for Vifor Pharma and Seqirus entities in due course.
